| ［1］ |
Gupta N, Kumar R, Agrawal B. New players in immunity to tuberculosis: the host microbiome, lung epithelium, and innate immune cells［J］. Front Immunol, 2018,9:709. doi: 10.3389/fimmu.2018.00709.
|
| ［2］ |
Evangelatos G, Koulouri V, Iliopoulos A, et al. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors［J］. Ther Adv Musculoskelet Dis, 2020,12:1759720X20930116. doi: 10.1177/1759720X20930116.
|
| ［3］ |
Domingo⁃Gonzalez R, Prince O, Cooper A, et al. Cytokines and chemokines in Mycobacterium tuberculosis infection［J］. Microbiol Spectr, 2016,4（5）: 10.1128/microbiolspec.TBTB2⁃0018⁃2016. doi: 10.1128/microbiolspec.TBTB2⁃0018⁃2016.
|
| ［4］ |
Cantini F, Nannini C, Niccoli L, et al. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non⁃anti⁃TNF⁃targeted biologics［J］. Mediators Inflamm, 2017,2017:8909834. doi: 10.1155/2017/8909834.
|
| ［5］ |
Griffiths Christopher EM, Armstrong April W, Gudjonsson Johann E, et al. Psoriasis［J］. Lancet, 2021,397:1301⁃1315. doi: 10. 1016/S0140⁃6736（20）32549⁃6.
|
| ［6］ |
肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识［J］. 中华风湿病学杂志, 2013,17（8）:508⁃512. doi: 10.3760/cma.j.issn.1007⁃7480.2013.08.002.
|
| ［7］ |
Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion［J］. Cell Mol Immunol, 2017,14（12）:963⁃975. doi: 10.1038/cmi.2017.88.
|
| ［8］ |
Stutz MD, Allison CC, Ojaimi S, et al. Macrophage and neutrophil death programs differentially confer resistance to tuberculosis［J］. Immunity, 2021,54（8）:1758⁃1771.e7. doi: 10.1016/j.immuni. 2021.06.009.
|
| ［9］ |
Dobler CC. Biologic agents and tuberculosis［J］. Microbiol Spectr, 2016,4（6）:10.1128/microbiolspec.TNMI7⁃0026⁃2016. doi: 10.1128/microbiolspec.TNMI7⁃0026⁃2016.
|
| ［10］ |
Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts（ESGICH） Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective（Soluble immune effector molecules ［I］: anti⁃tumor necrosis factor⁃α agents）［J］. Clin Microbiol Infect, 2018,24（Suppl 2）:S10⁃S20. doi: 10.1016/j.cmi.2017.12.025.
|
| ［11］ |
Goel N, Torralba K, Downey C, et al. Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California［J］. Clin Rheumatol, 2020,39（8）:2291⁃2297. doi: 10.1007/s10067⁃020⁃04991⁃y.
|
| ［12］ |
Fallahi⁃Sichani M, Flynn JL, Linderman JJ, et al. Differential risk of tuberculosis reactivation among anti⁃TNF therapies is due to drug binding kinetics and permeability［J］. J Immunol, 2012,188（7）:3169⁃3178. doi: 10.4049/jimmunol.1103298.
|
| ［13］ |
Floss DM, Moll JM, Scheller J. IL⁃12 and IL⁃23⁃close relatives with structural homologies but distinct immunological functions［J］. Cells, 2020,9（10）:2184. doi: 10.3390/cells9102184.
|
| ［14］ |
López⁃Ferrer A, Laiz A, Puig L. The safety of ustekinumab for the treatment of psoriatic arthritis［J］. Expert Opin Drug Saf, 2017,16（6）:733⁃742. doi: 10.1080/14740338.2017.1323864.
|
| ［15］ |
Jung SW, Lim SH, Jeon JJ, et al. Comparison of the efficacy and safety of biologics（secukinumab, ustekinumab, and guselkumab） for the treatment of moderate⁃to⁃severe psoriasis: real⁃world data from a single korean center［J］. Biomedicines, 2022,10（5）:1058. doi: 10.3390/biomedicines10051058.
|
| ［16］ |
Kaneko S, Tsuruta N, Yamaguchi K, et al. Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: real⁃world data from 18 Japanese facilities［J］. J Dermatol, 2020,47（2）:128⁃132. doi: 10.1111/1346⁃8138.15156.
|
| ［17］ |
Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double⁃blind, placebo⁃controlled, phase 2 study［J］. Lancet, 2018,391（10136）:2213⁃2224. doi: 10.1016/S0140⁃6736（18）30952⁃8.
|
| ［18］ |
Crowley JJ, Warren RB, Cather JC. Safety of selective IL⁃23p19 inhibitors for the treatment of psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1676⁃1684. doi: 10.1111/jdv.15653.
|
| ［19］ |
Reich K, Warren RB, Iversen L, et al. Long⁃term efficacy and safety of tildrakizumab for moderate⁃to⁃severe psoriasis: pooled analyses of two randomized phase III clinical trials（reSURFACE 1 and reSURFACE 2） through 148 weeks［J］. Br J Dermatol, 2020,182（3）:605⁃617. doi: 10.1111/bjd.18232.
|
| ［20］ |
Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate⁃to⁃severe plaque psoriasis: pooled analysis of three randomized controlled trials［J］. Br J Dermatol, 2018,179（3）:615⁃622. doi: 10.1111/bjd.16724.
|
| ［21］ |
Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate⁃to⁃severe plaque psoriasis（IMMvent）: a randomised, double⁃blind, active⁃comparator⁃controlled phase 3 trial［J］. Lancet, 2019,394（10198）:576⁃586. doi: 10.1016/S0140⁃6736（19）30952⁃3.
|
| ［22］ |
Torrado E, Cooper AM. IL⁃17 and Th17 cells in tuberculosis［J］. Cytokine Growth Factor Rev, 2010,21（6）:455⁃462. doi: 10.1016/j.cytogfr.2010.10.004.
|
| ［23］ |
Kammüller M, Tsai TF, Griffiths CE, et al. Inhibition of IL⁃17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections［J］. Clin Transl Immunology, 2017,6（8）:e152. doi: 10.1038/cti.2017.34.
|
| ［24］ |
Segueni N, Tritto E, Bourigault ML, et al. Controlled Mycobacterium tuberculosis infection in mice under treatment with anti⁃IL⁃17A or IL⁃17F antibodies, in contrast to TNFα neutralization［J］. Sci Rep, 2016,6:36923. doi: 10.1038/srep36923.
|
| ［25］ |
Blauvelt A, Lebwohl MG, Bissonnette R. IL⁃23/IL⁃17A dysfunction phenotypes inform possible clinical effects from anti⁃IL⁃17A therapies［J］. J Invest Dermatol, 2015,135（8）:1946⁃1953. doi: 10.1038/jid.2015.144.
|
| ［26］ |
Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate⁃to⁃severe psoriasis through 5 years of treatment（SCULPTURE Extension Study）［J］. J Eur Acad Dermatol Venereol, 2018,32（9）:1507⁃1514. doi: 10.1111/jdv.14878.
|
| ［27］ |
Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate⁃to⁃severe plaque psoriasis: a multi⁃center, retrospective, real⁃life study up to 52 weeks observation［J］. Expert Opin Biol Ther, 2018,18（7）:727⁃735. doi: 10.1080/14712598.2018.1481503.
|
| ［28］ |
Fowler E, Ghamrawi RI, Ghiam N, et al. Risk of tuberculosis reactivation during interleukin⁃17 inhibitor therapy for psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1449⁃1456. doi: 10.1111/jdv.16254.
|
| ［29］ |
Romiti R, Valenzuela F, Chouela EN, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis［J］. Br J Dermatol, 2019,181（1）:202⁃203. doi: 10.1111/bjd.17604.
|
| ［30］ |
Mrowietz U, Riedl E, Winkler S, et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: a report from 16 clinical studies of patients with psoriasis or psoriatic arthritis［J］. J Am Acad Dermatol, 2020,83（5）:1436⁃1439. doi: 10.1016/j.jaad.2020.06. 012.
|
| ［31］ |
Kelsey A, Chirch LM, Payette MJ. Tuberculosis and interleukin blocking monoclonal antibodies: is there risk?［J］. Dermatol Online J, 2018,24（9）:13030/qt58j4n38m.
|
